account63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account